Akero Therapeutics Inc (NASDAQ: AKRO) kicked off on Monday, down -7.29% from the previous trading day, before settling in for the closing price of $49.12. Over the past 52 weeks, AKRO has traded in a range of $17.86-$58.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -17.80%. With a float of $66.61 million, this company’s outstanding shares have now reached $72.38 million.
The extent of productivity of a business whose workforce counts for 63 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Akero Therapeutics Inc (AKRO) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Akero Therapeutics Inc is 11.34%, while institutional ownership is 91.35%. The most recent insider transaction that took place on Feb 18 ’25, was worth 498,660. In this transaction Chief Development Officer of this company sold 10,000 shares at a rate of $49.87, taking the stock ownership to the 95,648 shares. Before that another transaction happened on Feb 10 ’25, when Company’s President and CEO sold 30,000 for $52.73, making the entire transaction worth $1,581,994. This insider now owns 686,062 shares in total.
Akero Therapeutics Inc (AKRO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -17.80% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -6.13% during the next five years compared to -5.28% drop over the previous five years of trading.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Take a look at Akero Therapeutics Inc’s (AKRO) current performance indicators. Last quarter, stock had a quick ratio of 19.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -4.75 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
The latest stats from [Akero Therapeutics Inc, AKRO] show that its last 5-days average volume of 0.81 million was inferior to 1.55 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 21.35%. Additionally, its Average True Range was 2.85.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 65.30%, which indicates a significant increase from 0.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.13% in the past 14 days, which was lower than the 120.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $39.02, while its 200-day Moving Average is $29.78. Now, the first resistance to watch is $47.72. This is followed by the second major resistance level at $49.91. The third major resistance level sits at $51.03. If the price goes on to break the first support level at $44.41, it is likely to go to the next support level at $43.29. The third support level lies at $41.10 if the price breaches the second support level.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
The company with the Market Capitalisation of 3.42 billion has total of 69,799K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -151,760 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -72,710 K.
